Brain cross‐protection against SARS‐CoV‐2 variants by a lentiviral vaccine in new transgenic mice

COVID‐19 vaccines already in use or in clinical development may have reduced efficacy against emerging SARS‐CoV‐2 variants. In addition, although the neurotropism of SARS‐CoV‐2 is well established, the vaccine strategies currently developed have not taken into account protection of the central nervo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Min‐Wen, Authié, Pierre, Bourgine, Maryline, Anna, François, Noirat, Amandine, Moncoq, Fanny, Vesin, Benjamin, Nevo, Fabien, Lopez, Jodie, Souque, Philippe, Blanc, Catherine, Fert, Ingrid, Chardenoux, Sébastien, Lafosse, llta, Cussigh, Delphine, Hardy, David, Nemirov, Kirill, Guinet, Françoise, Langa Vives, Francina, Majlessi, Laleh, Charneau, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646827/
https://www.ncbi.nlm.nih.gov/pubmed/34647691
http://dx.doi.org/10.15252/emmm.202114459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646827/
https://www.ncbi.nlm.nih.gov/pubmed/34647691
http://dx.doi.org/10.15252/emmm.202114459

Ejemplares similares